Navigation Links
Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
Date:6/30/2010

Therapure Biopharma Inc. today announced an agreement under which Therapure will provide development services for Diamedica Incorporated, a biopharmaceutical company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide cell line development and protein production services to support clinical development for one of Diamedica’s products, a protein which may be used for the treatment of diabetes and neurological disorders. The companies are also negotiating contracts for on-going GMP manufacturing services. Financial terms were not disclosed.

Toronto, ON (Vocus) June 30, 2010 -- Therapure Biopharma Inc. today announced an agreement under which Therapure will provide development services for Diamedica Incorporated, a biopharmaceutical company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide cell line development and protein production services to support clinical development for one of Diamedica’s products, a protein which may be used for the treatment of diabetes and neurological disorders. The companies are also negotiating contracts for on-going GMP manufacturing services. Financial terms were not disclosed.

DiaMedica Inc. (DiaMedica) is a Canada-based biopharmaceutical company focused on developing treatments for diseases with significant unmet need including diabetes and neurological diseases. The Company has been selected as one of Canada’s Top 10™ life science companies in 2007/2008 and 2008/2009 by the Ottawa Centre for Research and Innovation (OCRI) and has several compounds in various stages of development.

“We are proud to have been chosen by Diamedica as its partner to provide cell line development and protein production services” said Thomas Wellner, President and CEO of Therapure. “Therapure has performed similar services for a number of clients and has demonstrated market leading expertise,” continued Mr. Wellner.

'Diamedica was seeking a cell line developer with the scientific expertise to handle this specialty product,' said Rick Pauls, CEO of Diamedica Inc. 'This project is important to DiaMedica’s future success and we are confident in Therapure’s ability to meet our needs'.

About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, please visit: www.therapurebio.com

# # #

Read the full story at http://www.prweb.com/releases/biopharma/manufacturing/prweb4204774.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
5. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
6. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
7. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):